This announcement is a separate document:
丰原药业：安徽径桥律师事务所关于公司2022年限制性股票激励计划第一个解除限售期限售条件成就、调整回购价格等相关事项的法律意见书
Fengyuan Pharmaceutical: Anhui Jingqiao Law Firm\'s legal opinion on matters related to the company\'s 2022 restricted stock incentive plan, the first lifting of sales restrictions, sales conditions, and the adjustment of repurchase prices
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.